Kolon Life Science Inc (KQ:102940) — Market Cap & Net Worth
Market Cap & Net Worth: Kolon Life Science Inc (102940)
Kolon Life Science Inc (KQ:102940) has a market capitalization of $108.62 Million (₩160.29 Billion) as of September 18, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #18959 globally and #904 in its home market, demonstrating a -3.70% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Kolon Life Science Inc's stock price ₩14050.00 by its total outstanding shares 11408200 (11.41 Million). Also see 102940 total asset value for a full breakdown of the balance sheet.
Kolon Life Science Inc Market Cap History: 2015 to 2026
Kolon Life Science Inc's market capitalization history from 2015 to 2026. Data shows change from $989.61 Million to $108.62 Million (-16.58% CAGR). Also see 102940 cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Kolon Life Science Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$233.34 Billion | 0.05% | #358 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$233.34 Billion | 0.05% | #358 of 1384 |
Weight: Kolon Life Science Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Kolon Life Science Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Kolon Life Science Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Kolon Life Science Inc share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.00x
Kolon Life Science Inc's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $989.61 Million | $121.18 Billion | $800.14 Million | 0.01x | 1.24x |
| 2016 | $605.09 Million | $158.28 Billion | $12.67 Billion | 0.00x | 0.05x |
| 2017 | $815.64 Million | $118.10 Billion | -$1.40 Billion | 0.01x | N/A |
| 2018 | $575.97 Million | $132.68 Billion | -$50.69 Billion | 0.00x | N/A |
| 2019 | $139.55 Million | $148.54 Billion | -$92.32 Billion | 0.00x | N/A |
| 2020 | $224.59 Million | $129.41 Billion | -$43.20 Billion | 0.00x | N/A |
| 2021 | $334.37 Million | $165.49 Billion | -$1.37 Billion | 0.00x | N/A |
| 2022 | $211.83 Million | $161.58 Billion | $2.13 Billion | 0.00x | 0.10x |
| 2023 | $198.69 Million | $124.64 Billion | -$30.73 Billion | 0.00x | N/A |
| 2024 | $177.82 Million | $161.39 Billion | -$93.09 Billion | 0.00x | N/A |
Competitor Companies of 102940 by Market Capitalization
Companies near Kolon Life Science Inc in the global market cap rankings as of September 18, 2026. Review how tangible is Kolon Life Science Inc's equity to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Kolon Life Science Inc by market ranking:
- Sam Chun Dang Pharm. Co. Ltd (KQ:000250): Ranked #5752 globally with a market cap of $2.26 Billion USD ( ₩3.34 Trillion KRW).
- ST Pharm Co.Ltd (KQ:237690): Ranked #8322 globally with a market cap of $1.14 Billion USD ( ₩1.69 Trillion KRW).
- NatureCell Co.Ltd (KQ:007390): Ranked #9400 globally with a market cap of $895.63 Million USD ( ₩1.32 Trillion KRW).
- Oscotec Inc (KQ:039200): Ranked #10937 globally with a market cap of $654.17 Million USD ( ₩965.30 Billion KRW).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #5752 | Sam Chun Dang Pharm. Co. Ltd | KQ:000250 | $2.26 Billion | ₩156100.00 |
| #8322 | ST Pharm Co.Ltd | KQ:237690 | $1.14 Billion | ₩90400.00 |
| #9400 | NatureCell Co.Ltd | KQ:007390 | $895.63 Million | ₩24900.00 |
| #10937 | Oscotec Inc | KQ:039200 | $654.17 Million | ₩34350.00 |
Kolon Life Science Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Kolon Life Science Inc's market cap moved from $989.61 Million to $ 108.62 Million, with a yearly change of -16.58%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩108.62 Million | -72.82% |
| 2025 | ₩399.70 Million | +124.78% |
| 2024 | ₩177.82 Million | -10.51% |
| 2023 | ₩198.69 Million | -6.20% |
| 2022 | ₩211.83 Million | -36.65% |
| 2021 | ₩334.37 Million | +48.88% |
| 2020 | ₩224.59 Million | +60.94% |
| 2019 | ₩139.55 Million | -75.77% |
| 2018 | ₩575.97 Million | -29.38% |
| 2017 | ₩815.64 Million | +34.80% |
| 2016 | ₩605.09 Million | -38.86% |
| 2015 | ₩989.61 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Kolon Life Science Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $108.62 Million USD |
| MoneyControl | $108.62 Million USD |
| MarketWatch | $108.62 Million USD |
| marketcap.company | $108.62 Million USD |
| Reuters | $108.62 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Kolon Life Science Inc
Kolon Life Science Inc. provides biopharmaceuticals, active pharmaceutical ingredients, pyrithione antimicrobials, and water solutions primarily in South Korea. Its biopharmaceutical product under development comprise KLS-1020, a cancer vaccine; KLS-3021, a oncolytic viral therapy; and KLS-2031 for treatment for neuropathic pain. The company also provides active pharmaceutical ingredients for ant… Read more